Theranostics2016 4th Theranostics World Congress 2016 Innovative Theranostics (17 abstracts)
Glioma tumors grade II/III – local alpha emiters targeted therapy with 213Bi-DOTA-substance P
Leszek LK Krolicki 1 , Alfred AM Morgenstern 1, , Jolanta JK Kunikowska 1 , Henryk HK Koziara 3 , Krolicki BK Bartosz 3 , Maciej MJ Jakucinski 4 , Dariusz DP Pawlak 5 , Constantinos CA Apostolidis 2 & Frank FB Bruchertseifer 2
1Medical University Warsaw, Warsaw, Masovia, Poland; 2European Commission, Joint Research Centre, Institute for Transuranium Elements, Karlsruhe, Germany; 3Department of Neurosurgery, Institute of Psychiatry and Neurology, Warsaw, Poland; 4Department of Imaging Diagnosis, Masovia Hospital, Warsaw, Poland; 5Radioisotope Centre POLATOM National Centre for Nuclear Research, Otwock, Poland.
Gliomas are a highly heterogeneous group of brain tumours that are refractory to treatment, and highly invasive. The treatment and prognosis depend upon the tumor grade. Treatment of Grade II/III gliomas typically consists of maximal safe resection, followed by external beam radiation therapy. Although less aggressive than GBM, mortality is high with a 5-year survival rate of only 25.9%. Glioma tumors has been demonstrated NK-1 receptor system and substance P can be used as a ligand for targeted therapy. Alpha emitter, like 213Bi offers the new potential for selective irradiation of tumors, with minimizing damage to adjacent tissue.
Material and methods: 50 patients with different glia tumors were treated in the study. Gliomas grade II/III was diagnosed in 12 patients with symptoms of progression of disease despite of standard therapy were performed. Following intracavitary or intratumoral insertion of catheter system, patients were treated with 2–8 doses of 2 GBq 213Bi-DOTA-Substance P (213Bi-SP) in intervals of 2 months. 68Ga-DOTA-Substance P (68Ga-SP) was co-injected with the therapeutic doses to assess biodistribution using PET/CT. Therapeutic response was monitored with MRI. Study was approved by the ethical committee of the Medical University of Warsaw.
Results: Treatment with activity up to 13 GBq 213Bi-SP was tolerated well with only mild transient adverse reactions. PET/CT imaging showed high retention of the radiolabeled peptide at the tumor site.
Median progression free survival was 5.5 months. Median overall survival from the first symptoms of recurrence was 32.7 months, Survival time from the start of 213Bi-SP was 30.2 months. Follow up of therapeutic responses and toxicity is continued and patient recruitment is ongoing.
Conclusions: Treatment of II/III grade gliomas with 213Bi-SP is safe and well tolerated. Targeted alpha therapy with 213Bi-SP may evolve as a promising novel option for treatment of II/III grade gliomas.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more